Jason Pitarresi to Disease Models, Animal
This is a "connection" page, showing publications Jason Pitarresi has written about Disease Models, Animal.
Connection Strength
0.371
-
Pitarresi JR, Stanger BZ. Cellular Origins and Lineage Plasticity in Cancer. Cold Spring Harb Perspect Med. 2024 Jun 03; 14(6).
Score: 0.138
-
Wu J, Liu X, Nayak SG, Pitarresi JR, Cuiti?o MC, Yu L, Hildreth BE, Thies KA, Schilling DJ, Fernandez SA, Leone G, Ostrowski MC. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. PLoS One. 2017; 12(9):e0184984.
Score: 0.087
-
Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Saeid A, Higashihara T, Wu F, Kumar A, Annamalai V, Bhattacharya S, Raman P, Adkisson CA, Pitarresi JR, Wengyn MD, Yamazoe T, Li J, Balli D, LaRiviere MJ, Ngo TC, Folkert IW, Millstein ID, Bermeo J, Carpenter EL, McAuliffe JC, Oktay MH, Brekken RA, Lowe SW, Iacobuzio-Donahue CA, Notta F, Stanger BZ. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Cancer Discov. 2022 02; 12(2):542-561.
Score: 0.029
-
Tang Q, Efe G, Chiarella AM, Leung J, Chen M, Yamazoe T, Su Z, Pitarresi JR, Li J, Islam M, Karakasheva T, Klein-Szanto AJ, Pan S, Hu J, Natsugoe S, Gu W, Stanger BZ, Wong KK, Diehl JA, Bass AJ, Nakagawa H, Murphy ME, Rustgi AK. Mutant p53 regulates Survivin to foster lung metastasis. Genes Dev. 2021 04 01; 35(7-8):528-541.
Score: 0.028
-
Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020 10; 30(10):764-776.
Score: 0.026
-
Park D, Shakya R, Koivisto C, Pitarresi JR, Szabolcs M, Kladney R, Hadjis A, Mace TA, Ludwig T. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One. 2019; 14(12):e0226714.
Score: 0.025
-
Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018 02; 67(2):320-332.
Score: 0.020
-
Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget. 2015 Dec 29; 6(42):44509-22.
Score: 0.019